Internal Medicine Alert
RSSArticles
-
Elinzanetant Capsules (Lynkuet)
The U.S. Food and Drug Administration has approved elinzanetant, a second non-hormonal neurokinin receptor antagonist, following fezolinetant (Veozah), for the treatment of vasomotor symptoms associated with menopause. Elinzanetant is distributed by Bayer HealthCare Pharmaceuticals, Inc., as Lynkuet.
-
Ambulatory Glucose Monitoring a Risk for Bloodborne Pathogens
A report of acute hepatitis B virus infection in a skilled nursing facility diabetes patient in North Carolina prompted an investigation for potential exposures and assessment of infection prevention practices in the facility.
-
Fleas, Typhus, and Texas
Cases of flea-borne typhus are dramatically increasing in Texas.
-
Detection of Atrial Fibrillation in Cryptogenic Stroke
The ANTARCTICA study is a pooled meta-analysis from multiple prospective studies of patients with ischemic stroke of varying etiologies, where loop monitoring was performed for atrial fibrillation detection. The groups were divided into cryptogenic stroke/transient ischemic attack or non-cryptogenic stroke/non-stroke. Both groups demonstrated an unadjusted rate of atrial fibrillation of about 30%.
-
Spironolactone for the Treatment of Acne Vulgaris
In this meta-analysis of 563 patients from five randomized controlled trials, objective assessment of acne improvement was higher in the spironolactone group compared to the placebo group (odds ratio, 6.59; 95% confidence interval, 3.50-12.43).
-
Early vs. Late Catheter Ablation for Atrial Fibrillation in Older Patients
An observational study from China in older patients with persistent atrial fibrillation (AF) has shown that an earlier diagnosis to catheter ablation time of ≤ 12 months compared to > 12 months is associated with lower rates of AF recurrence and adverse cardiovascular outcomes.
-
The History Matters!
How would you interpret today’s 12-lead electrocardiogram and long lead V1 rhythm strip if the history was that of an older adult with known coronary disease? Would your interpretation change if, instead, the patient was a younger adult with a known history of severe congenital heart disease, having been operated on a number of times as a child?
-
Paltusotine (Palsonify) Tablets
The U.S. Food and Drug Administration has approved paltusotine, the second oral (after octreotide), but first once-daily formulation for the treatment of acromegaly in adults.
-
Recombinant Herpes Zoster Vaccine in a Medicare Population
Receipt of adjuvanted recombinant herpes zoster vaccine was effective in individuals older than 64 years of age and maintained its efficacy in immunocompromised individuals. Added benefit accrued from receipt of the second vaccine dose, even if its administration was delayed.
-
COVID-19 Rebound: To Retreat or to Re-Treat
Re-treatment of non-immunocompromised patients with mild-moderate COVID-19 rebound with nirmatrelvir/ritonavir provided no significant benefit.